How big is the Prostate Cancer Diagnostics And Therapy Market?

The Prostate Cancer Diagnostics And Therapy Market size is expected to reach USD 13.24 billion in 2024 and grow at a CAGR of 8.80% to reach USD 20.19 billion by 2029. Read More

What is the current Prostate Cancer Diagnostics And Therapy Market size?

In 2024, the Prostate Cancer Diagnostics And Therapy Market size is expected to reach USD 13.24 billion. Read More

Who are the key players in Prostate Cancer Diagnostics And Therapy Market?

Bayer AG, AstraZeneca PLC, Sanofi-Aventis, Thermo Fisher Scientific and F. Hoffmann-La Roche Ltd. are the major companies operating in the Prostate Cancer Diagnostics And Therapy Market. Read More

Which is the fastest growing region in Prostate Cancer Diagnostics And Therapy Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Prostate Cancer Diagnostics And Therapy Market?

In 2024, the North America accounts for the largest market share in Prostate Cancer Diagnostics And Therapy Market. Read More

What years does this Prostate Cancer Diagnostics And Therapy Market cover, and what was the market size in 2023?

In 2023, the Prostate Cancer Diagnostics And Therapy Market size was estimated at USD 12.07 billion. The report covers the Prostate Cancer Diagnostics And Therapy Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Prostate Cancer Diagnostics And Therapy Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Prostate Cancer Diagnostics And Therapy Market Share

Statistics for the 2023 & 2024 Prostate Cancer Diagnostics And Therapy market share, created by Mordor Intelligence™ Industry Reports. Prostate Cancer Diagnostics And Therapy share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Prostate Cancer Diagnostics And Therapy Industry

The market for prostate cancer diagnostics and therapy is highly competitive due to the presence of a number of market players. Several large drug and equipment manufacturers exist within the global prostate cancer diagnostic and therapy market, and their status as major players lies primarily within specific product markets. Some of the key players in the market include Abbott Laboratories, Astellas Inc., AstraZeneca, Bayer HealthCare AG, Cellanyx Diagnostics Inc., Dendreon Corporation, Ferring Pharmaceuticals, Ipsen Group, Sanofi-Aventis, Tolmar Inc, GE Healthcare, Siemens Healthineers, and F. Hoffmann-La Roche AG.